What is William Blair's Forecast for APLS Q3 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at William Blair issued their Q3 2024 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a report released on Wednesday, October 16th. William Blair analyst L. Hanbury-Brown expects that the company will earn ($0.26) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.37) per share. William Blair also issued estimates for Apellis Pharmaceuticals' Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($1.25) EPS and FY2025 earnings at $0.34 EPS.

Several other brokerages also recently issued reports on APLS. Wedbush increased their price target on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, August 9th. Mizuho lowered their target price on Apellis Pharmaceuticals from $42.00 to $39.00 and set a "neutral" rating for the company in a research note on Friday, September 20th. Robert W. Baird dropped their target price on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an "outperform" rating on the stock in a report on Monday, September 23rd. The Goldman Sachs Group upped their price target on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the company a "buy" rating in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an "overweight" rating on the stock in a report on Friday, September 13th. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $68.00.

Apellis Pharmaceuticals Trading Up 0.3 %

Shares of APLS stock traded up $0.08 on Friday, hitting $28.00. The stock had a trading volume of 1,508,102 shares, compared to its average volume of 1,657,443. The firm has a market cap of $3.40 billion, a P/E ratio of -8.09 and a beta of 0.87. Apellis Pharmaceuticals has a twelve month low of $26.28 and a twelve month high of $73.80. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73. The company has a fifty day moving average price of $34.34 and a two-hundred day moving average price of $39.84.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.03. The firm had revenue of $199.70 million during the quarter, compared to analysts' expectations of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business's revenue for the quarter was up 110.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.02) earnings per share.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC lifted its stake in shares of Apellis Pharmaceuticals by 471.5% during the 3rd quarter. CWM LLC now owns 23,722 shares of the company's stock worth $684,000 after buying an additional 19,571 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in Apellis Pharmaceuticals by 15.5% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,600 shares of the company's stock valued at $796,000 after acquiring an additional 3,700 shares during the period. Duncan Williams Asset Management LLC acquired a new stake in Apellis Pharmaceuticals during the third quarter worth approximately $609,000. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Apellis Pharmaceuticals during the second quarter worth approximately $725,000. Finally, Algert Global LLC grew its position in shares of Apellis Pharmaceuticals by 137.8% in the second quarter. Algert Global LLC now owns 123,628 shares of the company's stock valued at $4,742,000 after purchasing an additional 71,650 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors.

Insider Activity at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the business's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares in the company, valued at $3,623,000. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.80% of the stock is owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).